Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 378 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR No Clinically Meaningful Difference in Survival Between Nivolumab Plus Ipilimumab and... September 20, 2023 Job Loss During Cancer: How to Cope and Continue Treatment September 24, 2020 EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... May 23, 2024 Study Suggests Statins May Help Keep Breast Cancer from Spreading to... June 24, 2020 Load more HOT NEWS FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF... p53 Mutations May Differentially Affect Survival of Patients with mCRC Based... 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... Banking on breakthroughs for children and young people
